ASC30 is Ascletis’ investigational once-daily oral small molecule GLP-1 receptor agonist, with company-reported Phase 2 findings and a Phase 3 program underway, but no reported regulatory approval.
ASC30 research has moved beyond a future-trial announcement. The important update is that Ascletis has reported early clinical findings and begun AURORA, its larger confirmatory program. That deserves a careful look, with the evidence labels firmly attached. A press release can tell us what the sponsor observed. It cannot do the job of a full research paper.
ASC30 oral GLP-1: small molecule, not peptide
ASC30 targets GLP-1 receptors, but it is not a peptide. Think of the receptor as a molecular doorbell: different chemical designs can ring it. Sharing a biological target does not make those designs the same substance. This distinction gets lost when every metabolic research headline lands in the same peptide bucket.
The phrase “oral GLP-1 pill” describes a formulation category, not a chemical identity. ASC30 Ascletis research concerns a small molecule. Readers exploring that category can find Xcel’s earlier orforglipron article. For another small-molecule candidate, see the aleniglipron research overview. These links supply background; separate trials do not establish comparative clinical performance.
Company-reported ASC30 trial facts
The figures below are reported by the sponsor. The obesity Phase 2 findings were also presented in a 2026 conference abstract, which provides less detail than a full clinical report. Amounts describe trial protocols only. The listed weight and HbA1c changes are placebo-adjusted; adverse-event discontinuation rates are group-specific rates.
| Study | Design and amounts used in the trial | Company-reported findings |
|---|---|---|
| Obesity Phase 2 NCT07002905 |
Company-reported: 125 adults; 13 weeks; baseline weight 107.3 kg. Amounts used in the trial: 20, 40 or 60 mg once daily, with weekly escalation from 1 mg. | Company-reported: body-weight reductions 5.4%, 7.0%, 7.7%, respectively. Adverse-event discontinuations 7.3%, 7.5%, 0%, versus 0% placebo; 4.8% overall. |
| Diabetes Phase 2 NCT07321678 |
Company-reported: 100 adults; amounts used in the trial: 40, 60 or 80 mg once daily. Efficacy-analysis group sizes: 20, 29, 28. | Company-reported: week-12 HbA1c reductions 1.7, 1.6, 1.7 percentage points; week-13 body-weight reductions 4.4%, 3.8%, 4.0%. No gastrointestinal-event discontinuations; 1 of 80 discontinued for any adverse event. |
| AURORA Phase 3 NCT07743463 / NCT07743450 |
Company-reported plan: about 4,600 adults across both trials; 72 weeks. Amounts used in the trial: 20, 40 or 60 mg once daily, or placebo. | Company-reported: first participant announced August 30, 2026. Topline findings expected Q3 2028. These are plans and milestones, not completed findings. |
What the findings actually tell us
Placebo-adjusted means the reported change accounts for the placebo group’s change. It is not the same as the total change from baseline. HbA1c, a blood-glucose marker, also needs careful labeling: percentage points describe the difference between two percentages. Quiet detail, big difference in meaning.
The diabetes announcement uses an efficacy estimand, an analysis framed around eligible randomized participants adhering to study treatment. The table’s analysis-group counts should therefore not be mistaken for a complete participant-flow report. Likewise, no discontinuations for a particular adverse-event category does not mean that category never occurred.
In the separate 13-week obesity study, the Ascletis conference poster reported nausea in 49%, 63% and 40% and vomiting in 22%, 25% and 30% of the 20, 40 and 60 mg ASC30 groups, respectively. These are sponsor-reported group rates, not individual predictions. The poster compares results across different trials; that comparison does not establish superior tolerability to orforglipron. A full study report and longer-term safety data remain important.
ASC30 Phase 3: the timeline
AURORA is underway, rather than merely planned. Ascletis’ milestones put the December 2025 obesity findings before the August 2026 Phase 3 start and October 2026 diabetes findings. AURORA-1 excludes type 2 diabetes; AURORA-2 includes it. The sponsor anticipates an FDA submission by late 2028 and an EU submission in early 2029. Submission is not approval.
Related research reading
For the wider landscape, see the obesity research pipeline overview, Petrelintide ZUPREME update, UBT251 Phase 2 analysis and Eloralintide research guide. Xcel’s catalog page is separate from the sponsor’s clinical program and requires account access for logged-out visitors. For Ascletis’ separate triple agonist peptide program, see our ASC37 research update.
ASC30 FAQ
Is ASC30 a peptide?
No. ASC30 is a small molecule GLP-1 receptor agonist. A receptor target does not determine whether a compound is a peptide.
What did ASC30 Phase 2 research report?
Ascletis reported placebo-adjusted changes in body weight in an obesity trial and in HbA1c and body weight in a type 2 diabetes trial. The obesity findings also appear in a conference abstract. Full clinical study reports were not available in the sources reviewed.
Has ASC30 Phase 3 started?
Yes. Ascletis announced the first participant in the AURORA Phase 3 program on August 30, 2026. Completed Phase 3 results remain unavailable.
Is ASC30 approved?
ASC30 remains investigational as of November 2, 2026, with no regulatory approval reported in the reviewed primary sources.
When are AURORA results expected?
Ascletis forecasts topline findings in the third quarter of 2028. That is a company timeline, which may change, rather than a guaranteed completion or approval date.
All products supplied by Xcel Research LLC are chemical reference materials intended solely for in vitro laboratory research. They are not drugs, foods, dietary supplements, cosmetics, or medical devices, and have not been approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease or condition. These materials are not for human or veterinary use and may not be administered to humans or animals under any circumstances.